Germline


Journal

Journal of medical genetics
ISSN: 1468-6244
Titre abrégé: J Med Genet
Pays: England
ID NLM: 2985087R

Informations de publication

Date de publication:
01 2021
Historique:
received: 22 11 2019
revised: 12 02 2020
accepted: 14 02 2020
pubmed: 18 3 2020
medline: 11 9 2021
entrez: 18 3 2020
Statut: ppublish

Résumé

Although considerable effort has been put into decoding of the osteosarcoma genome, very little is known about germline mutations that underlie this primary malignant tumour of bone. We followed here a coincidental finding in a multiple endocrine neoplasia family in which a 32-year-old patient carrying a germline pathogenic After Li-Fraumeni-predisposing mutations in

Sections du résumé

BACKGROUND
Although considerable effort has been put into decoding of the osteosarcoma genome, very little is known about germline mutations that underlie this primary malignant tumour of bone.
METHODS AND RESULTS
We followed here a coincidental finding in a multiple endocrine neoplasia family in which a 32-year-old patient carrying a germline pathogenic
CONCLUSIONS
After Li-Fraumeni-predisposing mutations in

Identifiants

pubmed: 32179705
pii: jmedgenet-2019-106734
doi: 10.1136/jmedgenet-2019-106734
doi:

Substances chimiques

MAS1 protein, human 0
Proto-Oncogene Mas 0
RB1 protein, human 0
Retinoblastoma Binding Proteins 0
TP53 protein, human 0
Tumor Suppressor Protein p53 0
Ubiquitin-Protein Ligases EC 2.3.2.27
Proto-Oncogene Proteins c-ret EC 2.7.10.1
RET protein, human EC 2.7.10.1

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

20-24

Informations de copyright

© Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Auteurs

Michal Kovac (M)

Institute for Medical Genetics and Pathology, University Hospital Basel, Basel, Switzerland michal.kovac@usb.ch.

Connor Woolley (C)

Cancer Genetics and Evolution Laboratory, Edinburgh Cancer Research Centre, Edinburgh, UK.
Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK.

Sebastian Ribi (S)

Institute for Medical Genetics and Pathology, University Hospital Basel, Basel, Switzerland.

Claudia Blattmann (C)

Pediatrics 5 (Oncology, Hematology, Immunology), Klinikum Stuttgart Olgahospital, Stuttgart, Germany.
Department of Pediatric Hematology, Oncology, Immunology and Pulmology, University of Heidelberg, Heidelberg, Germany.

Eva Roth (E)

Department of Pediatric Hematology, Oncology, Immunology and Pulmology, University of Heidelberg, Heidelberg, Germany.

Marco Morini (M)

Department of Biomedicine, University of Basel, Basel, Switzerland.

Monika Kovacova (M)

Institute of Mathematics and Physics, Faculty of Mechanical Engineering, Slovak University of Technology, Bratislava, Slovakia.

Baptiste Ameline (B)

Institute for Medical Genetics and Pathology, University Hospital Basel, Basel, Switzerland.

Andreas Kulozik (A)

Department of Pediatric Hematology, Oncology, Immunology and Pulmology, University of Heidelberg, Heidelberg, Germany.

Stefan Bielack (S)

Pediatrics 5 (Oncology, Hematology, Immunology), Klinikum Stuttgart Olgahospital, Stuttgart, Germany.

Wolfgang Hartmann (W)

Gerhard Domagk Institute of Pathology, University Hospital Münster, Münster, Germany.

Mandy L Ballinger (ML)

Genomic Cancer Medicine Laboratory, The Kinghorn Cancer Center and Garvan Institute of Medical Research, Darlinghurst, New South Wales, Australia.

David M Thomas (DM)

Genomic Cancer Medicine Laboratory, The Kinghorn Cancer Center and Garvan Institute of Medical Research, Darlinghurst, New South Wales, Australia.

Ian Tomlinson (I)

Cancer Genetics and Evolution Laboratory, Edinburgh Cancer Research Centre, Edinburgh, UK.
Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK.

Michaela Nathrath (M)

Department of Pediatric Hematology and Oncology, Klinikum Kassel, Kassel, Germany.
Department of Pediatrics, Technical University Munich, Munich, Germany.

Karl Heinimann (K)

Institute for Medical Genetics and Pathology, University Hospital Basel, Basel, Switzerland.

Daniel Baumhoer (D)

Institute for Medical Genetics and Pathology, University Hospital Basel, Basel, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH